Liquidia (NASDAQ:LQDA) Sees Strong Trading Volume

Shares of Liquidia Co. (NASDAQ:LQDA) saw an uptick in trading volume on Tuesday . 1,838,476 shares were traded during mid-day trading, an increase of 110% from the previous session’s volume of 876,653 shares.The stock last traded at $13.18 and had previously closed at $12.21.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on LQDA. HC Wainwright reaffirmed a “buy” rating and issued a $32.00 price objective on shares of Liquidia in a research note on Wednesday, July 10th. Needham & Company LLC dropped their target price on Liquidia from $28.00 to $25.00 and set a “buy” rating for the company in a report on Thursday, August 8th. Finally, Oppenheimer initiated coverage on Liquidia in a report on Tuesday, June 25th. They issued a “market perform” rating for the company. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, Liquidia has an average rating of “Moderate Buy” and a consensus price target of $21.00.

Liquidia Stock Performance

The stock has a fifty day moving average of $12.22 and a 200-day moving average of $13.32. The company has a market cap of $1.06 billion, a PE ratio of -8.87 and a beta of 0.32.

Liquidia (NASDAQ:LQDA) last posted its quarterly earnings data on Monday, May 13th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.22). Liquidia had a negative net margin of 674.42% and a negative return on equity of 177.83%. The business had revenue of $2.97 million for the quarter, compared to analysts’ expectations of $4.31 million. As a group, equities analysts anticipate that Liquidia Co. will post -1.39 EPS for the current fiscal year.

Insider Activity at Liquidia

In related news, CFO Michael Kaseta sold 3,906 shares of the business’s stock in a transaction on Friday, July 12th. The stock was sold at an average price of $12.53, for a total transaction of $48,942.18. Following the completion of the transaction, the chief financial officer now owns 312,389 shares in the company, valued at approximately $3,914,234.17. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Liquidia news, CFO Michael Kaseta sold 3,906 shares of the company’s stock in a transaction on Friday, July 12th. The stock was sold at an average price of $12.53, for a total value of $48,942.18. Following the completion of the sale, the chief financial officer now directly owns 312,389 shares in the company, valued at approximately $3,914,234.17. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Roger Jeffs sold 8,053 shares of the company’s stock in a transaction on Friday, July 12th. The stock was sold at an average price of $12.53, for a total value of $100,904.09. Following the completion of the sale, the chief executive officer now owns 818,932 shares of the company’s stock, valued at $10,261,217.96. The disclosure for this sale can be found here. Insiders sold a total of 21,437 shares of company stock worth $268,549 in the last quarter. 31.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On Liquidia

Several hedge funds have recently made changes to their positions in LQDA. Cerity Partners LLC bought a new position in shares of Liquidia in the 4th quarter worth $197,000. Simplicity Solutions LLC raised its position in shares of Liquidia by 45.6% in the 4th quarter. Simplicity Solutions LLC now owns 31,193 shares of the company’s stock worth $375,000 after acquiring an additional 9,764 shares in the last quarter. Greenleaf Trust bought a new position in shares of Liquidia in the 4th quarter worth $164,000. New York State Common Retirement Fund raised its position in shares of Liquidia by 124.6% in the 4th quarter. New York State Common Retirement Fund now owns 19,312 shares of the company’s stock worth $232,000 after acquiring an additional 10,714 shares in the last quarter. Finally, BNP Paribas Financial Markets raised its position in shares of Liquidia by 19.1% in the 4th quarter. BNP Paribas Financial Markets now owns 104,933 shares of the company’s stock worth $1,262,000 after acquiring an additional 16,843 shares in the last quarter. 64.54% of the stock is currently owned by hedge funds and other institutional investors.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).